Olaparib is an oral poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme involved in DNA repair, and inhibition of PARP leads to an accumulation of DNA damage in cancer cells, ultimately causing cell death. Olaparib is particularly effective in cancers that have deficiencies in DNA repair mechanisms, such as those with BRCA1 or BRCA2 mutations.
Treatment of BRCA-Mutated Ovarian Cancer.
Maintenance Therapy for Platinum-Sensitive Recurrent Ovarian Cancer.
Treatment of BRCA-Mutated Breast Cancer.
Treatment of BRCA-Mutated Metastatic Pancreatic Cancer.
Treatment of BRCA-Mutated Metastatic Prostate Cancer.